About
Norovirus Vaccine
Areas of Focus
Categories
VaccineBoston & New England
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
3,514
By Phase
PHASE1: 1PHASE2: 1PHASE2/PHASE3: 2
By Status
COMPLETED: 3TERMINATED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT06007781Lead Sponsor
Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants
PHASE1Completed
21 participants
Started: Aug 18, 2023 · Completed: May 27, 2024
NCT05972733Lead Sponsor
Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults
PHASE2Completed
80 participants
Started: Aug 1, 2023 · Completed: Nov 10, 2023
NCT05836012Lead Sponsor
Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines
PHASE2/PHASE3Completed
329 participants
Started: Jun 10, 2023 · Completed: Jul 8, 2024
NCT05281094Lead Sponsor
Efficacy and Safety of Two Doses of HIL-214 in Children
PHASE2/PHASE3Terminated
3,084 participants
Started: Apr 28, 2022 · Completed: Sep 30, 2024
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...